Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2014

Optimierung der Antibiotika-Therapie - Behandlung mittels Dauerinfusion

1. Van Herendael, B. et al. Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? Ann Intensive Care 2012; 2: 22-24
    

2. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
   Roberts, J. A. et al. Clin Infect Dis 2014; 58:1072-1083
    

3. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.
   Roberts, J. A. et al. Lancet Infect Dis 2014;14:498-509
    

4. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics.
   Roberts, J. a. et al. Crit Care Med 2009; 37:2071-2078
    
5. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
   Dulhunty, J. M. et al. Clin Infect Dis 2013; 56:236-244
    

6. Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
   Cutro, S. R. et al. Antimicrob Agents Chemother 2014; 58:4470-447
    

7. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
   Hughes, D. M. et al. Antimicrob Agents Chemother 2009; 53: 2014-2019
    
8. High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.
   Nesseler, N. et al. Antimicrob Agents Chemother 2014; 58: 5448-5455
    
9. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
   Roberts, J. A. et al. J Antimicrob Chemother 2007;59: 285-291
    
10. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.
    Bauer, K. A. et al. Antimicrob Agents Chemother 2013; 57:2907-12
     
11. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente, L. et al. Ann Pharmacother 2006; 40:219-223
     
12. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.
    Feher, C. et al. J Antimicrob Chemother 2014; 69:2556-2562
     
13. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone, F. S. et al. Crit Care 2010; 14(4):R126
     
14. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
    Liu, C. et al. Clin Infect Dis 2011;52:e18-55

Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2014

Kombinationstherapie bei Infektionen mit Carbapenem-resistenten Erregern

1. Zavascki, AP et al., Combination therapy for carbapenem-resistant Gram-negative bacteria.

Expert Rev. Antiinfect. Ther. 2013; 11:1333-1353

2. Zavascki, AP, Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.

Expert Rev Anti Infect Ther. 2014; 12:531-533

3. Qureshi, ZA et al., Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Antimicrob Agents Chemother 2012;56:2108-2113

4. Wiskirchen, DE et al., Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.

Int J Antimicrob Agents 2013;41:582-585

5. Falagas, ME, Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.

Clin Microbiol Infect. 2006; 12:1227-1230

6. Tasina, E et al., Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.

Lancet Inf Dis 2011; 11:834-844

7. Pharmacia, 2013. Fachinformation Tygacil^®

siehe auch:

Tygacil, Summary of Product Characteristics (EMA)

8. Ramirez, J et al., Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

Antimicrob Agents Chemother 2013; 57: 1756-1762

9. Lee, YT et al., Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.

Eur J Clin Microbiol Inf Dis 2013; 32:1211-1220

10. Karageorgopoulos, DE et al., Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012; 67: 2777-2779

11. Aydemir, H et al., Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141:1214-1222

12. Durante-Mangoni, E et al.,Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.

Clin Inf Dis 2013;57:349–358

13. Jaruratanasirikul, S et al., Pharmacodynamics modeling to optimize dosage regimens of sulbactam.

Antimicrob Agents Chemother 2013; 57:3441-3444

14. Batirel, A et al., Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

Eur J Clin Microbiol Infect Dis. 2014;33:1311-1322

Literaturangaben zum Übersichtsartikel aus

Heft 4 / 2013

25 Jahre antiretrovirale Therapie:

vom AZT zur einmal täglichen

Kombinationstherapie

1: Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013 Feb-Mar;21(1):6-14.

2: Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012 Jul-Sep;14(3):168-78

3: Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387-402

4: Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6.

5: Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M; Swiss HIV Cohort Study.. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med. 2012 Sep 24;172(17):1313-21.

6. Häussler B et al.

Arzneimittel-Atlas 2012, S. 180-183

7: Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85

Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2013

Dauer der Antibiotikatherapie: kürzere  Behandlung, gleiche Erfolge

1. HAYASHI, Y. und PATERSON, D.L

Clin Inf Dis 2011; 52:1232-1240

2. EL MOUSSAOUI, R. et al.

Brit Med J 2006;332:1355-1360

3. CARRATALA, J. et al.

Arch Intern Med 2012; 172:922-928

4. CHASTRE, J. et al.

JAMA 2003; 290:2588-2598

5. TALAN, D.A. et al.

JAMA 2000;283:1583-1590

6. SCHUETZ, P. et al.

Clin Inf Dis 2012; 55:651-662

7. SCHUETZ, P. et al.

JAMA 2009; 302:1059-1066

8. HAVEY, T.C. et al.

Crit Care 2011; 15:R267

9. DANEMAN, N. et al.

JAMA Intern Med 2013; 173:673-682